click below
click below
Normal Size Small Size show me how
Antifungal study
for peds pharm
| Question | Answer |
|---|---|
| Amphotericin B formulation | IV only |
| Amphotericin B MOA | binds to ergosterol in fungus cell wall causing leakage and death |
| Amphotericin B Kinetics | Poor PO abs. Poor CNS penetration. Highly protein bound. Elimination?? Renal, feces, bile. Do not adjust dose for renal/ liver issues |
| Amphotericin B Dosing | 0.5-1mg/kg/day Dosing dependent of disease being treated. Duration dependent on location of infection. 10-40 days |
| Amphotericin B coverage | candida albicans, candida tropicalis, candida parapsilosis Aspergillus, histoplasmosis, blastomycosis, Cryptoccus neoformans |
| Amphotericin B infusion related side effects | fever, chills, H/A, muscle aches, phlebitis. Premed with tylenol, benedryl, demoral for rigers & fluid bolus with NS to protect kidneys |
| Amphotericin B non infusion realted side effects | Anticipated: hypo K+, hypo Mg+ Observed: anemia, thrombocytopenia, seizures, renal failure |
| Rx to treat Aspergillus | Amphotericin B |
| Rx to treat histoplasmosis | Amphotericin B |
| Rx to treat candida albicans, candida tropicalis, candida parapsilosis | Amphotericin B |
| Rx to treat Cryptoccus neoformans | Amphotericin B |
| 3 names for Lipid amphotericin | abelcet, amphotec, ambisome |
| % pt who experience renal dysfunction from amphotericin B | 25-30% |
| % pt who experience renal dysfunction from lipid amphotericin | 10-15% |
| Infusion time for amphotericin B | 4 hrs |
| Infusion time for amphotericin lipid | 2 hrs |
| Flucytosine MOA | anti fungal: interferes with fungal RNA, DNA & protein synthesis |
| Flucytosine Kinetics | Good CNS penetration (75% of serum), elimination renal 75-90%, monitor levels 25-100mcg/ml |
| Flucytosine uses | synergy with amphotericin B |
| Flucytosine SE | bone marrow suppression @ high levels, LFT ^, hypoK+, hypoglycemic. |
| Fluconazole MOA | inhibits ergosterol production = inhibit cell wall formation |
| Fluconazole CSF penetration | good |
| Fluconazole SE | N/V, H/A, rash, diarrhea, ^LFT |
| Organisms sensitive to fluconazole | candida albicans, cryptococcos |
| Fluconazole formulations | IV & PO NB:100% bioavaliablity PO |
| Ketoconazole formulations | PO, Shampoo, creams |
| Ketoconazole uses | cradle cap, tinnea |
| Ketoconazole MOA | inhibits ergosterol production = inhibit cell wall formation |
| Ketoconazole kinetics | absorption pH dependent (needs low pH) if on H1 or PPI won't work Poor CSF penetration, metabolized in liver excreted in bili & feces |
| Ketoconazole SE | liver toxic, N/V, abdominal pain |
| voriconazole formulations | IV, PO |
| voriconazole MOA | inhibits ergosterol production = inhibit cell wall formation |
| Voriconazole kinetics | 96% PO availability, good CSF penetration, metabolized in the liver,p 450, excreted in bili & feces |
| voriconazole SE | vision changes (blurred photophobia), rash, ^LFT, hepatitis, cholestasis, ARF, hypoK+, photosensitivity, Preg cat D, cardiac arrhythmias, QT prolongation |
| Posaconazole MOA | inhibits ergosterol production = inhibit cell wall formation |
| Posaconazole kinetics | food increases absorption, Lare Vd, highly protein bound, metabolized in liver t1/2=35 hrs, excretion =>70% in stool (66% unchanged) |
| Posaconazole SE | edema, HTN, QT prolongation, hypoK+, Hypo Mg+, hypo Ca, ^ glucose, severe diarrhea, vomiting, mucositis, anemia, neutropenia, thromocytopenia, Liver toxic ^LFT, ^bili, Hepatitis, weakness, tremor |
| Caspofungin MOA | inhibits enzume 1,3-beta-Dglucan synthases which forms glucan -polymer of glucose molecules which are necessary for cell wall syntheses |
| Caspofungin coverage | broad spectrum, good 2nd line agent after ampho |
| Caspofungin kinetics | Iv only, hightly protein bound 97%, metabolised in liver, excreted as inactive metabolite 41% urine, 35% stool |
| caspofugin formulations | IV only |
| caspofungin SE | fever (3-26%) vein irritation (15%) N/V, headache, puritis, rash, histamine related infusion reactions, hypoK+ anemia, ^LFT |
| Caspofungin is incompatible with what carrier fluid | dextrose |
| Griseofulvin MOA | inhibits mitosis by disrupting cells mitotic spindle structure |
| Griseofulvin uses | tinea capitis |
| Griseofulvin administration | shake very well falls out of suspension, need fat to absorb, not well absorbed |